Stock index futures slide on Thursday.» Read More
Dec 2- Forest Laboratories Inc, which is facing patent expirations on several of its biggest drugs, on Monday said it plans to buy rights to a new schizophrenia treatment from Merck& Co and cut annual operating costs by $500 million in fiscal 2016..
Baxter International Inc. rose$. 74 or 1.1 percent, to $69.19. Bristol-Myers Squibb Co. fell$. 13 or. 3 percent, to $51.25. Hospira rose$. 50 or 1.3 percent, to $39.81.
Dec 2- Forest Laboratories Inc, which is facing patent expirations on several of its biggest drugs, on Monday said it planned to buy rights to a new schizophrenia drug from Merck& Co and cut its annual operating costs by $500 million in 2016..
Baxter International Inc. rose$. 23 or. 3 percent, to $68.45. Bristol-Myers Squibb Co. fell$. 29 or. 6 percent, to $51.38. Hospira fell$. 12 or. 3 percent, to $39.31.
Baxter International Inc. rose$. 23 or. 3 percent, to $68.45. Bristol-Myers Squibb Co. fell$. 29 or. 6 percent, to $51.38. Hospira fell$. 10 or. 3 percent, to $39.33.
Baxter International Inc. rose$. 03 or percent, to $68.25. Bristol-Myers Squibb Co. rose$. 16 or. 3 percent, to $51.83. Hospira rose$. 07 or. 2 percent, to $39.50.
LONDON, Nov 22- European regulators have recommended approval of a new drug from Gilead Sciences to treat hepatitis C and an HIV medicine from GlaxoSmithKline, both of which are expected to be major sellers.
Some of the names on the move ahead of the open.
But use of Merck& Co's widely prescribed Zetia, which is not a statin, and Vytorin, a related drug, will likely not be badly hurt anytime soon, analysts said, because doctors will need time to understand and accept the new guidelines. The Merck drugs have combined annual sales of more than $4 billion, or 10 percent of overall company revenue.
Pfizer Inc, Amgen Inc and a partnership of Regeneron Inc and French drugmaker Sanofi SA are racing to develop the new family of medicines called PCSK9 inhibitors. "I read the new guidelines as a negative for any drugs that aren't statins, including PCSK9 inhibitors," said Jon LeCroy, an analyst with MKM Partners.
Focused on high-risk heart attack and stroke patients, the new recommendation are for aggressive drug therapy to lower cholesterol.
The number of planned layoffs at U.S. firms rose 13.5 percent in October on cuts in the pharmaceutical and financial sectors, a report on Wednesday showed.
"Mad Money" host Jim Cramer made calls on stocks viewers asked about.
LONDON- Even as the euro zone economy shows faint signs of stirring, the European Central Bank is likely to send a dovish message this week that more monetary help will be on the way before long. Embraer probed for bribery in Argentine, Dominican deals.
DALLAS, Nov 3- For more than a century, ranchers and their children have paraded cattle around the dusty show ring at the State Fair of Texas in Dallas, in a rite of passage that is part farm economics, part rural theater.
Oct 31- U.S. pharmaceutical giant Merck& Co faces significant challenges bringing its controversial feed additive Zilmax back to market in the United States and Canada, even after a vote of confidence from South Korea on Thursday.
*South Korea currently bans controversial animal feed zilpaterol. SEOUL, Oct 31- South Korea plans to end its ban on the animal feed additive zilpaterol early next year, a senior food ministry official said on Thursday, opening the door to beef imports containing the growth enhancer and its domestic sale.
CHICAGO, Oct 30- Cargill Inc, one of the world's largest beef processors, threw a wrench into Merck& Co.' s plans to reintroduce its feed additive Zilmax, stating it will not accept Zilmax-fed beef into the Cargill supply chain "until we are 100 percent confident the animal welfare issues are resolved."
CHICAGO, Oct 30- Agribusiness giant Cargill Inc said on Wednesday that it will not buy cattle fed Merck& Co Inc's controversial cattle-feed additive, Zilmax, and will not feed it to its own cattle, until it is "100 percent confident" the animal welfare issues are resolved.
Oct 30- Parexel International Corp's shares fell as much as 18 percent after the drug research services provider said it struggled to win new contracts when rivals reported strong results and raised their forecasts.